As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
|Articles|October 9, 2014
Unlocking the True Value of Big Data
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more...
Advertisement
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more…
Advertisement
Related to this article
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5